Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT

Abstract

There is interest in optimizing peptide receptor radionuclide therapy (PRRT) for the management of metastatic neuroendocrine neoplasms (NEN). The addition of stereotactic body radiation therapy (SBRT) may provide synergistic benefit by targeting specific sites of disease that may represent areas of tumor heterogeneity. Little is known around the efficacy or potential toxicity of this approach. An institutional retrospective review of patients with NEN treated with sequential PRRT and SBRT was performed to provide preliminary outcome and toxicity data to inform further treatment and clinical trial strategies combining these therapies.